Physician profile
Megan Schwartz
NPI 1538665229
$4,591.92
in general payments reported to CMS, 2019-2025
33 companies · $1,906 in 2025
The $1,906 reported for 2025 was more than what 92% of Addiction Medicine (Family Medicine) providers received nationally (typical 2025 total: $143).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $255 · 2023: $880 · 2024: $1,550 · 2025: $1,906.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,337.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,337.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $948.77 | 2022-2025 | Vraylar, Ubrelvy |
| Glaxosmithkline, LLC. | $422.11 | 2022-2025 | Shingrix, Arexvy, Bexsero |
| Lilly USA, LLC | $367.63 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Viiv Healthcare Company | $317.28 | 2024-2025 | Apretude |
| Amgen INC. | $243.71 | 2024-2025 | Evenity, Repatha, Otezla |
| Pfizer INC. | $242.42 | 2023-2025 | |
| Gilead Sciences, INC. | $224.34 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $201.90 | 2024-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $190.08 | 2024-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $160.47 | 2022-2025 | Verquvo, Capvaxive, Gardasil 9 |
| Inspire Medical Systems, INC. | $158.16 | 2022-2024 | Inspire |
| Janssen Pharmaceuticals, INC | $114.40 | 2023-2025 | Spravato, Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $112.48 | 2023-2025 | |
| Astellas Pharma US INC | $96.10 | 2024-2025 | Veozah |
| Novo Nordisk INC | $95.68 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $79.16 | 2022-2025 | Nexplanon |
| Indivior INC. | $70.78 | 2023 | Sublocade |
| Astrazeneca Pharmaceuticals Lp | $67.79 | 2024-2025 | Airsupra, Breztri |
| Hologic Sales and Service, LLC | $62.63 | 2024-2025 | Thinprep 2000 Processor, Aptima |
| Medtronic, INC. | $62.35 | 2022-2025 | Inceptiv, Minimed 780g |
| Boston Scientific Corporation | $52.16 | 2023-2024 | Wavewriter Alpha Prime 16 |
| Xeris Pharmaceuticals, INC. | $45.95 | 2023-2024 | Gvoke Hypopen |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $40.46 | 2025 | Caplyta |
| Cranial Technologies, INC | $36.32 | 2022-2023 | Doc Band |
| Idorsia Pharmaceuticals US INC | $29.09 | 2023-2024 | Quviviq |
| Phathom Pharmaceuticals, INC. | $23.17 | 2025 | Voquezna |
| Verona Pharma, INC. | $22.00 | 2025 | Ohtuvayre |
| Shield Therapeutics INC | $20.46 | 2024 | |
| Axsome Therapeutics, INC. | $20.04 | 2025 | Auvelity |
| Dexcom, INC. | $19.31 | 2025 | Dexcom G6 Transmitter |
| Sanofi Pasteur INC. | $18.59 | 2024 | |
| Verity Pharmaceuticals INC. | $13.94 | 2025 | Tlando |
| Takeda Pharmaceuticals U.S.A., INC. | $12.19 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Schwartz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.